Skip to content
value.today

Compugen Ltd.

CGEN.TA
$174 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$73 M
For year ending December-2025
Net income
$35 M
48.6% margin
SEC filing
Employees
—

Compugen Ltd. in brief

Compugen Ltd. is a listed company in the Biotechnology industry, based in Israel. It was founded in 1993. Its last known market value was $174 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $73 M and a net profit of $35 M, about 49 cents of profit for every dollar of sales. Its largest business segments by sales in 2025 were Single Operating (100%). Its shares trade under the symbol CGEN.TA (Tel Aviv).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Compugen Ltd.

Compugen Ltd. (Hebrew: קומפיוג'ן) is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Compugen Ltd. timeline

2 events, 1993–2000
  1. 1993
  2. 🏁
    · approximate
    Founded
  3. 2000
  4. 🔔
    · approximate
    Initial public offering on Tel Aviv

Events of Compugen Ltd. from Wikidata and the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$271 M$541 M$812 M$1.1 B20202021202220232024

World rank over time

▼ down 5,960 places since 2020
2020-01-01: #12651#12,65120202021-01-01: #7944#7,94420212022-01-07: #15665#15,66520222022-12-25: #23713#23,71320222023-07-30: #22007#22,00720232024-01-05: #18611#18,6112024

Rank in Israel: #113 (Jan 2020) · #60 (Jan 2021) · #180 (Jan 2022) · #281 (Dec 2022) · #254 (Jul 2023) · #199 (Jan 2024)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
—
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
48.6%
Operating margin
43.1%
Return on equity
34.4%
Liabilities / assets
34.4%
Revenue growth
+161.2%
R&D / revenue
31.3%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $18M, net income $-23M$18MFY18Fiscal year ending Dec 2019: revenue —, net income $-27M—FY19Fiscal year ending Dec 2020: revenue $2M, net income $-30M$2MFY20Fiscal year ending Dec 2021: revenue $6M, net income $-34M$6MFY21Fiscal year ending Dec 2022: revenue $8M, net income $-34M$8MFY22Fiscal year ending Dec 2023: revenue $33M, net income $-19M$33MFY23Fiscal year ending Dec 2024: revenue $28M, net income $-14M$28MFY24Fiscal year ending Dec 2025: revenue $73M, net income $35M$73MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$73M+161.2%$31M$35M48.6%
Dec 2024$28M-16.7%$-15M$-14M-51.1%
Dec 2023$33M+346.1%$-13M$-19M-56.0%
Dec 2022$8M+25.0%$-35M$-34M-449.2%
Dec 2021$6M+200.0%$-35M$-34M-570.0%
Dec 2020$2M—$-32M$-30M-1485.0%
Dec 2019——$-29M$-27M—
Dec 2018$18M—$-23M$-23M-127.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$32M$0M$31M$0.38—
Dec 2024$50M$0M$49M$-0.16—
Dec 2023$-36M$0M$-36M$-0.21—
Dec 2022$-34M$0M$-35M$-0.39—
Dec 2021$-23M$0M$-23M$-0.41—
Dec 2020$-28M$0M$-28M$-0.37—
Dec 2019$-28M$0M$-28M$-0.43—
Dec 2018$-13M$0M$-13M$-0.41—

SEC filings

Official filings of Compugen Ltd. with the US Securities and Exchange Commission.

Annual results

Revenue
$73 M
Operating income
$31 M
Net income
$35 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$157 M
Total liabilities
$54 M
Total equity
$103 M

As of December-2025

Mutual funds holding Compugen Ltd.#

14 funds hold shares worth $6 M. Since their previous reports 8 added shares and 4 sold, buying $0 M net.
Mutual funds holding Compugen Ltd.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Nomura Healthcare FundDelaware Management Company1.02 M$2 M—0.29%no changeJun 30, 2026
🇺🇸 ARK Israel Innovative Technology ETFARK Investment Management LLC887,867$2 M—1.5%+13%Jul 31, 2026
🇺🇸 State Street SPDR Portfolio Developed World ex-US ETFSSGA Funds Management, Inc.346,188$1 M—<0.01%−0.1%Jun 30, 2026
🇺🇸 International Core Equity 2 PortfolioDimensional Fund Advisors LP71,228$0 M—<0.01%+2.5%Jul 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC56,738$0 M—<0.01%+13%May 31, 2026
🇺🇸 State Street SPDR S&P International Small Cap ETFSSGA Funds Management, Inc.63,080$0 M—0.02%+1.0%Jun 30, 2026
🇺🇸 The Continental Small Company SeriesDimensional Fund Advisors LP19,304$0 M—<0.01%−25%Jul 31, 2026
🇺🇸 International Social Core Equity PortfolioDimensional Fund Advisors LP18,907$0 M—<0.01%newJul 31, 2026
🇺🇸 Dfa International Small Cap Value PortfolioDimensional Fund Advisors LP16,001$0 M—<0.01%newJul 31, 2026
🇺🇸 International Sustainability Core 1 PortfolioDimensional Fund Advisors LP14,192$0 M—<0.01%no changeJul 31, 2026
🇺🇸 International Vector Equity PortfolioDimensional Fund Advisors LP13,486$0 M—<0.01%+19%Jul 31, 2026
🇺🇸 World ex U.S. Core Equity PortfolioDimensional Fund Advisors LP10,412$0 M—<0.01%no changeJul 31, 2026
🇺🇸 Dimensional VA International Small PortfolioDimensional Fund Advisors LP8,383$0 M—<0.01%+130%Jul 31, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC4,200$0 M—<0.01%−11%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 14 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Compugen Ltd.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
0
0 purchases, 0 insiders
Sold, 12 months
118 K
11 sales, 2 insiders
Net, 12 months
-118 K
open market only
Insiders on file
10
since
-$89 K$0Mar 2026: bought $0 (0 trades), sold $24 K (1 trades)Mar 26Apr 2026: bought $0 (0 trades), sold $89 K (9 trades)AprJul 2026: bought $0 (0 trades), sold $5 K (1 trades)Jul
Bought (open market)Sold (open market)Hover a month for the totals
Compugen Ltd.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Savitzky Kinneret LivnatDirectorGrant or award+7,500——local20,850Form 4
filed Gilead HalevyDirectorGrant or award+7,500——local18,907Form 4
filed Michelle MahlerChief Medical OfficerGrant or award+13,500——local36,625Form 4
filed Sanford S. ZweifachDirectorGrant or award+7,500——local20,180Form 4
filed Zurit LevineSVP, Business DevelopmentGrant or award+18,000——local47,375Form 4
filed Mathias HukkelhovenDirectorGrant or award+7,500——local17,500Form 4
filed David SilbermanChief Financial OfficerGrant or award+19,500——local55,000Form 4
filed Eran PerryDirectorGrant or award+7,500——local17,500Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals. This company files with the SEC as a foreign issuer; its insiders often report prices in the home currency, so amounts are as filed and not converted to dollars

Markets and events: Compugen Ltd.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
2.5 M
2.7% of shares · 9.7 days to cover

Fails to deliver

  • : 158 shares at $2.12
  • : 463 shares at $2.14
  • : 12,221 shares at $2.34
  • : 4,548 shares at $2.38

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Compugen Ltd. scorecard#

Passes 11 of the 14 checks that could be worked out: strongest in growth (6 of 6), weakest in profitability (4 of 5). Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth6 of 6
    • ✓Revenue grew in the newest year161.2%Revenue up 161.2% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years113.3%113.3% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median113.3%113.3% a year against Biotechnology's median of 12.9% (181 companies).
    • ✓Earnings per share grew in the newest year0.38 vs -0.16Diluted EPS 0.38 in fiscal 2025 against -0.16 the year before (report's currency).
    • ✓Net income higher than five years earlier$35 M$35 M in fiscal 2025 against -$30 M in 2020.
    • ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
  • Profitability4 of 5
    • ✓Profitable in the newest year$35 MNet income $35 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • ✓Operating margin above its peers' median43.1%43.1% against Biotechnology's median of -60.5% (243 companies).
    • ✓Return on equity above 15%44.8%44.8% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier43.1%43.1% in fiscal 2025 against -471.6% in 2022.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities6.6×Current ratio 6.56 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years2 of 3Positive in 2 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year4.8%Diluted shares up 4.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Compugen Ltd.'s statements, beside the median of Biotechnology.

Compugen Ltd.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin43.1%-60.5%
Net margin48.6%-68.9%
Return on equity44.8%-61.0%
Revenue growth, 3 years a year113.3%12.9%
Revenue growth161.2%15.8%
Free cash flow margin43.1%-61.5%

6of 8on the Piotroski tests of financial strength

Compugen Ltd.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Compugen Ltd.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue7328337.56.02.0—18—0.7
Cost of revenue9.37.92.01.00.70.1—1.0—0.2
Gross profit6420316.55.31.9—17—0.5
Research and development23253431292320302925
Selling and marketing—————000.300
General and administrative8.99.49.710119.88.48.07.67.3
Operating expenses32354442403329403733
Operating income31−15−13−35−35−31−29−23−37−33
Interest and finance income3.93.53.01.40.91.80.90.60.50.7
Income before tax35−9.7−9.8−34−34−30−28−23−37−31
Income tax0.14.59.00.100−0.7——0.0
Net income attributable to shareholders35−14−19−34−34−30−27−23−37−32
Earnings per share, basic0.38-0.16-0.21-0.39-0.41-0.37-0.43-0.41-0.72-0.62
Earnings per share, diluted0.38-0.16-0.21-0.39-0.41-0.37-0.43-0.41-0.72-0.62
Shares, weighted average (basic)93908887848064555151
Shares, weighted average (diluted)94908887848064555151
Balance sheet
Cash and cash equivalents911814117.87.19.25.9259.7
Short-term investments9.324120——————
Receivables—0610—2.0————
Other current assets0.10.10.20.20.10.10.30.10.71.2
Current assets1481061158612312945473163
Property, plant and equipment0.70.91.21.51.71.72.33.44.66.0
Right-of-use (leased) assets2.52.81.31.82.22.83.2———
Non-current assets8.59.06.88.18.99.28.86.67.68.5
Total assets1571151219413213854533971
Accounts payable2.41.83.51.84.61.41.12.93.41.3
Current liabilities2320261217116.810.06.24.7
Lease liabilities (non-current)2.42.50.71.32.02.53.0———
Non-current liabilities3140304.68.48.08.65.93.32.9
Retained earnings−453−489−475−456−422−388−358−331−308−271
Shareholders' equity10355667810712038372964
Total liabilities and equity1571151219413213854533971
Shares outstanding95908987868468605151
Cash-flow statement
Share-based compensation1.93.03.64.34.32.82.42.22.63.1
Cash from operating activities3250−36−34r−23r−28−28−13−31−20
Capital expenditure−0.3−0.1−0.2−0.5−0.3−0.2−0.2−0.2−0.4−2.6
Cash from investing activities30−4636376.6−825.3−354616r
Shares issued110.53.1015742328——
Cash from financing activities110.63.10.41710826280.22.5
Exchange-rate effect on cash0.10.10.1−0.4−0.1—————
Change in cash724.02.82.90.7———16−1.2r
Report20-F20-F20-F20-F20-F20-F/A20-F/A20-F20-F20-F

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Compugen Ltd. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • Single Operating$73 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Acquisitions and funding#

Private share sales · funding history

Private share sales of Compugen Ltd.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2021$20 MPrivate placement after listing$10 to $50 million1equitySEC
Oct 2018$12 MPrivate placement after listing$10 to $50 million1equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Compugen Ltd. compares in Biotechnology

  • Revenue$73 M · higher than 65% of 647
  • Net margin48.6% · higher than 98% of 408
  • Revenue growth161.2% · higher than 88% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Compugen Ltd.🇮🇱$174 M—48.6%+161.2%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 16, 2026

Figures from SEC filing, Wikidata, value.today research, Wikipedia; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Compugen Ltd.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Compugen Ltd.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Compugen Ltd.? Suggest a correction